US5278202A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biodegradable in-situ forming implants and methods of producing the same
Assignee: Tolmar Therapeutics Inc
•
Filing: 1991-12-23
•
Granted: 1994-01-11
•
Expires: 2011-12-23
Abstract
Abstract A biodegradable polymer is provided for use in providing syringeable, in-situ forming, solid biodegradable implants for animals. The polymer is placed into the animal in liquid form and cures to form the implant in-situ. A thermoplastic system to form said implant comprises the steps of dissolving a non-reactive polymer in biocompatible solvent to form a liquid, placing the liquid within the animal, and allowing the solvent to dissipate to produce the implant. An alternative, thermosetting system comprises mixing together effective amounts of a liquid acrylic ester terminated, biodegradable prepolymer and a curing agent, placing the liquid mixture within an animal and allowing the prepolymer to cure to form the implant. Both systems provide a syringeable, solid biodegradable delivery system by the addition of an effective level of biologically active agent to the liquid before injection into the body.
Inventors
- 👤 Richard L. Dunn
- 👤 James P. English
- 👤 Donald R. Cowsar
- 👤 David D. Vanderbilt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61F; A61F2/00; A61K47/00; A61K47/30; A61K47/34; A61L; A61L15/00; A61L15/16; A61L15/42; A61L15/44; A61L15/62; A61L24/00; A61L24/001; A61L24/0015; A61L24/0026; A61L24/0042; A61L24/04; A61L24/046; A61L24/06; A61L26/00; A61L26/0009; A61L26/0019; A61L26/0061; A61L26/0066; A61L26/0076; A61L26/009; A61L27/00; A61L27/14; A61L27/16; A61L27/18; A61L27/26; A61L27/28; A61L27/34; A61L27/50; A61L27/54; A61L27/58; A61F2/02; A61F2/30; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30062; A61F2002/30316; A61F2002/30535; A61F2002/30581; A61F2002/30583; A61F2210/00; A61F2210/0004; A61F2210/0085; A61L2300/00; A61L2300/20; A61L2300/25; A61L2300/252; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/41; A61L2300/60; A61L2300/602; A61L2300/604; Y; Y10; Y10S; Y10S525/00; Y10S525/937
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
93 words
A pharmaceutical composition for forming a biodegradable pharmaceutically acceptable implant in-situ within a living body, comprising an effective amount of a pharmaceutically acceptable liquid acrylic-ester terminated prepolymer of terminal acryloyl groups and a residue of an oligomer having terminal functional groups capable of reacting with acryloyl acylating groups wherein the prepolymer is capable of being cured into said implant in-situ within a living body and the cured form of the prepolymer is water insoluble and is biodegradable by simple or enzymatically antalyzed hydrolysis; and an effective amount of a pharmaceutically acceptable curing agent.
Claim 2
Dependent Claim
93 words
A pharmaceutical composition for forming a biodegradable pharmaceutically acceptable implant in-situ within a living body, comprising an effective amount of a pharmaceutically acceptable liquid acrylic-ester terminated prepolymer of terminal acryloyl groups and a residue of an oligomer having terminal functional groups capable of reacting with acryloyl acylating groups wherein the prepolymer is capable of being cured into said implant in-situ within a living body and the cured form of the prepolymer is water insoluble and is biodegradable by simple or enzymatically antalyzed hydrolysis; and an effective amount of a pharmaceutically acceptable curing agent.
Claim 3
Dependent Claim
23 words
The composition of claim 1, wherein said liquid acrylic ester terminated prepolymer is a product of a conversion of a polyol-terminated biodegradable prepolymer.
Claim 4
Dependent Claim
23 words
The composition of claim 2, wherein said polyol-terminated biodegradable prepolymer is a product of co-polymerization of DL-lactide and ε-caprolactone with a polyol initiator.
Claim 5
Dependent Claim
23 words
The composition of claim 2, wherein said polyol-terminated biodegradable prepolymer is a product of co-polymerization of L-lactide and ε-caprolactone with a polyol initiator.
Claim 6
Dependent Claim
11 words
The composition of claim 1, wherein said curing agent is azobisisbutyronitrile.
Claim 7
Dependent Claim
12 words
The composition of claim 1, wherein said curing agent is benzoyl peroxide.
Claim 8
Dependent Claim
16 words
The composition of claim 1, and further comprising an effective amount of a biologically active agent.
Claim 9
Dependent Claim
22 words
The composition of claim 1, wherein said liquid acrylic-ester-terminated prepolymer is capable of being cured into said implant in-situ within a body.
Claim 10
Dependent Claim
9 words
The composition of claim 1, further comprising a filler.
Claim 11
Dependent Claim
49 words
The composition of claim 2, wherein said polyol-terminated prepolymer is selected from the group consisting essentially of polylactides, polyglycolides, polycaprolactones, polydioxanones, polycarbonates, polyhydroxybutyrates, polyalkylene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyketals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyorthoesters, and copolymers, terpolymers and combinations and mixtures thereof.
Claim 12
Dependent Claim
162 words
A pharmaceutical kit suitable for in-situ formation of a biodegradable implant in a body, which comprises: an effective amount of a liquid acrylic-ester terminated prepolymer of terminal acryloyl groups and oligomer having terminal functional groups capable of reacting with an acryloyl compound wherein the prepolymer is capable of being cured into said implant in-situ in the living body and the cured form of the prepolymer is water insoluble and is biodegradable by simple or enzymatically catalyzed hydrolysis; an effective amount of a curing agent in a suitable form for combination with the liquid prepolymer; and, a device for application of a liquid combination of the liquid prepolymer and curing agent, the device having a outlet for the liquid combination, an ejector for expelling the liquid combination through the outlet and a hollow tube fitted to the outlet for inserting the liquid combination into a site of the living body such that the liquid combination can form an implant in-situ at said site.
Claim 13
Dependent Claim
162 words
A pharmaceutical kit suitable for in-situ formation of a biodegradable implant in a body, which comprises: an effective amount of a liquid acrylic-ester terminated prepolymer of terminal acryloyl groups and oligomer having terminal functional groups capable of reacting with an acryloyl compound wherein the prepolymer is capable of being cured into said implant in-situ in the living body and the cured form of the prepolymer is water insoluble and is biodegradable by simple or enzymatically catalyzed hydrolysis; an effective amount of a curing agent in a suitable form for combination with the liquid prepolymer; and, a device for application of a liquid combination of the liquid prepolymer and curing agent, the device having a outlet for the liquid combination, an ejector for expelling the liquid combination through the outlet and a hollow tube fitted to the outlet for inserting the liquid combination into a site of the living body such that the liquid combination can form an implant in-situ at said site.
References Cited (Backward Citations)
US3760034A
Cited
US4148871A
Cited
US4408023A
Cited
JPS63137907A
Cited
US4983689A
Cited
US5077049A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-01-10 | 1997-07-12 | 1998-01-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-01-10 | 2001-07-12 | 2002-01-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-01-10 | 2005-07-12 | 2006-01-11 | $7700.00 | Window Closed / Lapsed |